20 julio 2015
Patients with a specific molecular subtype of diffuse large B-cell lymphoma are more likely to respond to the drug ibrutinib (Imbruvica) than patients with another molecular subtype of the disease, a new study shows.img src=»http://feeds.feedburner.com/~r/sciencedaily/~4/cYdwRrFwwsY» height=»1″ width=»1″ alt=»»/
http://feeds.sciencedaily.com/~r/sciencedaily/~3/cYdwRrFwwsY/150720114737.htm
